Current status of bevacizumab in advanced ovarian cancer

Ovarian cancer is the most lethal gynecological cancer, mainly because of the delay in diagnosis. Recently, much effort has been put into investigating and introducing novel targeted agents into clinical practice, with the aim of improving prognosis and quality of life. Angiogenesis is a possible ta...

Full description

Saved in:
Bibliographic Details
Published in:OncoTargets and therapy 2013-01, Vol.6, p.889-899
Main Authors: Tomao, Federica, Papa, Anselmo, Rossi, Luigi, Caruso, Davide, Panici, Pierluigi Benedetti, Venezia, Martina, Tomao, Silverio
Format: Article
Language:English
Subjects:
Angiogenesis
bevacizumab
chemotherapy
Drug therapy
epithelial ovarian cancer
Immunotherapy
Investigations
Medical case management
Medical research
Medicine, Experimental
Monoclonal antibodies
Ovarian cancer
Review
Targeted cancer therapy
Vascular endothelial growth factor
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 899
container_issue
container_start_page 889
container_title OncoTargets and therapy
container_volume 6
creator Tomao, Federica
Papa, Anselmo
Rossi, Luigi
Caruso, Davide
Panici, Pierluigi Benedetti
Venezia, Martina
Tomao, Silverio
description Ovarian cancer is the most lethal gynecological cancer, mainly because of the delay in diagnosis. Recently, much effort has been put into investigating and introducing novel targeted agents into clinical practice, with the aim of improving prognosis and quality of life. Angiogenesis is a possible target. The aim of this review is to investigate the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in patients with ovarian cancer. These therapeutic strategies include monoclonal antibodies and tyrosine-kinase inhibitors. These drugs have as molecular targets vascular endothelial growth factor, vascular endothelial growth factor receptors, platelet-derived growth factor, fibroblast growth factor, and angiopoietin. Bevacizumab was investigated in several Phase III studies, with interesting results. Today, there is strong evidence for introducing bevacizumab in the treatment of patients with advanced and recurrent ovarian cancer. Nevertheless, further investigations and large clinical trials are needed to understand the safety and effectiveness of bevacizumab, the optimal duration and timing of treatment, and activity in association with other chemotherapeutic and targeted agents. It also is necessary to identify biologic factors predictive of efficacy to choose the most appropriate antiangiogenic agent in the integrated treatment of epithelial ovarian cancer.
doi_str_mv 10.2147/OTT.S46301
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3724566</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A375815862</galeid><sourcerecordid>A375815862</sourcerecordid><originalsourceid>FETCH-LOGICAL-c504t-3973496297d80f14a3adae5160d7fbc3ab9e23a2a9f2bf21fe427de219cec2bd3</originalsourceid><addsrcrecordid>eNptkl2L1DAUhoso7rp64w-QgiAizJivpu3NwjL4BQt74XgdTpOTnSxtMiZtQX-9KbPuzojkIsnJ8745HN6ieE3JmlFRf7zZbtffheSEPinOKa2blWw5eXp0PitepHRHiJQNE8-LM8ZbQlnDz4tmM8WIfizTCOOUymDLDmfQ7vc0QFc6X4KZwWs0ZZghOvClXq7xZfHMQp_w1f1-Ufz4_Gm7-bq6vvnybXN1vdIVEeOKtzUXrWRtbRpiqQAOBrCikpjadppD1yLjwKC1rLOMWhSsNshoq1GzzvCL4vLgu5-6AY3OvUbo1T66AeIvFcCp0xfvduo2zIrXTFRSZgNyMDBhxn3ElE7Ej1UdBkUXVZa8v_8zhp8TplENLmnse_AYpqSooFK2FWMso2__Qe_CFH2eiMrPrG4YpdUjdQs9KudtyK3qxVRd8bpqaNXIxWv9Hyovg4PTwaN1uX4ieHck2CH04y6Ffhpd8OkU_HAAdQwpRbQPI6BELRlSOUPqkKEMvzme-AP6NzT8Dz8RwIE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2222782115</pqid></control><display><type>article</type><title>Current status of bevacizumab in advanced ovarian cancer</title><source>Open Access: PubMed Central</source><source>Taylor &amp; Francis_OA刊</source><source>Publicly Available Content Database</source><creator>Tomao, Federica ; Papa, Anselmo ; Rossi, Luigi ; Caruso, Davide ; Panici, Pierluigi Benedetti ; Venezia, Martina ; Tomao, Silverio</creator><creatorcontrib>Tomao, Federica ; Papa, Anselmo ; Rossi, Luigi ; Caruso, Davide ; Panici, Pierluigi Benedetti ; Venezia, Martina ; Tomao, Silverio</creatorcontrib><description>Ovarian cancer is the most lethal gynecological cancer, mainly because of the delay in diagnosis. Recently, much effort has been put into investigating and introducing novel targeted agents into clinical practice, with the aim of improving prognosis and quality of life. Angiogenesis is a possible target. The aim of this review is to investigate the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in patients with ovarian cancer. These therapeutic strategies include monoclonal antibodies and tyrosine-kinase inhibitors. These drugs have as molecular targets vascular endothelial growth factor, vascular endothelial growth factor receptors, platelet-derived growth factor, fibroblast growth factor, and angiopoietin. Bevacizumab was investigated in several Phase III studies, with interesting results. Today, there is strong evidence for introducing bevacizumab in the treatment of patients with advanced and recurrent ovarian cancer. Nevertheless, further investigations and large clinical trials are needed to understand the safety and effectiveness of bevacizumab, the optimal duration and timing of treatment, and activity in association with other chemotherapeutic and targeted agents. It also is necessary to identify biologic factors predictive of efficacy to choose the most appropriate antiangiogenic agent in the integrated treatment of epithelial ovarian cancer.</description><identifier>ISSN: 1178-6930</identifier><identifier>EISSN: 1178-6930</identifier><identifier>DOI: 10.2147/OTT.S46301</identifier><identifier>PMID: 23901283</identifier><language>eng</language><publisher>New Zealand: Dove Medical Press Limited</publisher><subject>Angiogenesis ; bevacizumab ; chemotherapy ; Drug therapy ; epithelial ovarian cancer ; Immunotherapy ; Investigations ; Medical case management ; Medical research ; Medicine, Experimental ; Monoclonal antibodies ; Ovarian cancer ; Review ; Targeted cancer therapy ; Vascular endothelial growth factor</subject><ispartof>OncoTargets and therapy, 2013-01, Vol.6, p.889-899</ispartof><rights>COPYRIGHT 2013 Dove Medical Press Limited</rights><rights>2013. This work is licensed under https://creativecommons.org/licenses/by-nc/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2013 Tomao et al, publisher and licensee Dove Medical Press Ltd 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2222782115/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2222782115?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23901283$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tomao, Federica</creatorcontrib><creatorcontrib>Papa, Anselmo</creatorcontrib><creatorcontrib>Rossi, Luigi</creatorcontrib><creatorcontrib>Caruso, Davide</creatorcontrib><creatorcontrib>Panici, Pierluigi Benedetti</creatorcontrib><creatorcontrib>Venezia, Martina</creatorcontrib><creatorcontrib>Tomao, Silverio</creatorcontrib><title>Current status of bevacizumab in advanced ovarian cancer</title><title>OncoTargets and therapy</title><addtitle>Onco Targets Ther</addtitle><description>Ovarian cancer is the most lethal gynecological cancer, mainly because of the delay in diagnosis. Recently, much effort has been put into investigating and introducing novel targeted agents into clinical practice, with the aim of improving prognosis and quality of life. Angiogenesis is a possible target. The aim of this review is to investigate the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in patients with ovarian cancer. These therapeutic strategies include monoclonal antibodies and tyrosine-kinase inhibitors. These drugs have as molecular targets vascular endothelial growth factor, vascular endothelial growth factor receptors, platelet-derived growth factor, fibroblast growth factor, and angiopoietin. Bevacizumab was investigated in several Phase III studies, with interesting results. Today, there is strong evidence for introducing bevacizumab in the treatment of patients with advanced and recurrent ovarian cancer. Nevertheless, further investigations and large clinical trials are needed to understand the safety and effectiveness of bevacizumab, the optimal duration and timing of treatment, and activity in association with other chemotherapeutic and targeted agents. It also is necessary to identify biologic factors predictive of efficacy to choose the most appropriate antiangiogenic agent in the integrated treatment of epithelial ovarian cancer.</description><subject>Angiogenesis</subject><subject>bevacizumab</subject><subject>chemotherapy</subject><subject>Drug therapy</subject><subject>epithelial ovarian cancer</subject><subject>Immunotherapy</subject><subject>Investigations</subject><subject>Medical case management</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Monoclonal antibodies</subject><subject>Ovarian cancer</subject><subject>Review</subject><subject>Targeted cancer therapy</subject><subject>Vascular endothelial growth factor</subject><issn>1178-6930</issn><issn>1178-6930</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkl2L1DAUhoso7rp64w-QgiAizJivpu3NwjL4BQt74XgdTpOTnSxtMiZtQX-9KbPuzojkIsnJ8745HN6ieE3JmlFRf7zZbtffheSEPinOKa2blWw5eXp0PitepHRHiJQNE8-LM8ZbQlnDz4tmM8WIfizTCOOUymDLDmfQ7vc0QFc6X4KZwWs0ZZghOvClXq7xZfHMQp_w1f1-Ufz4_Gm7-bq6vvnybXN1vdIVEeOKtzUXrWRtbRpiqQAOBrCikpjadppD1yLjwKC1rLOMWhSsNshoq1GzzvCL4vLgu5-6AY3OvUbo1T66AeIvFcCp0xfvduo2zIrXTFRSZgNyMDBhxn3ElE7Ej1UdBkUXVZa8v_8zhp8TplENLmnse_AYpqSooFK2FWMso2__Qe_CFH2eiMrPrG4YpdUjdQs9KudtyK3qxVRd8bpqaNXIxWv9Hyovg4PTwaN1uX4ieHck2CH04y6Ffhpd8OkU_HAAdQwpRbQPI6BELRlSOUPqkKEMvzme-AP6NzT8Dz8RwIE</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Tomao, Federica</creator><creator>Papa, Anselmo</creator><creator>Rossi, Luigi</creator><creator>Caruso, Davide</creator><creator>Panici, Pierluigi Benedetti</creator><creator>Venezia, Martina</creator><creator>Tomao, Silverio</creator><general>Dove Medical Press Limited</general><general>Taylor &amp; Francis Ltd</general><general>Dove Press</general><general>Dove Medical Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130101</creationdate><title>Current status of bevacizumab in advanced ovarian cancer</title><author>Tomao, Federica ; Papa, Anselmo ; Rossi, Luigi ; Caruso, Davide ; Panici, Pierluigi Benedetti ; Venezia, Martina ; Tomao, Silverio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c504t-3973496297d80f14a3adae5160d7fbc3ab9e23a2a9f2bf21fe427de219cec2bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Angiogenesis</topic><topic>bevacizumab</topic><topic>chemotherapy</topic><topic>Drug therapy</topic><topic>epithelial ovarian cancer</topic><topic>Immunotherapy</topic><topic>Investigations</topic><topic>Medical case management</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Monoclonal antibodies</topic><topic>Ovarian cancer</topic><topic>Review</topic><topic>Targeted cancer therapy</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tomao, Federica</creatorcontrib><creatorcontrib>Papa, Anselmo</creatorcontrib><creatorcontrib>Rossi, Luigi</creatorcontrib><creatorcontrib>Caruso, Davide</creatorcontrib><creatorcontrib>Panici, Pierluigi Benedetti</creatorcontrib><creatorcontrib>Venezia, Martina</creatorcontrib><creatorcontrib>Tomao, Silverio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>ProQuest_Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>OncoTargets and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tomao, Federica</au><au>Papa, Anselmo</au><au>Rossi, Luigi</au><au>Caruso, Davide</au><au>Panici, Pierluigi Benedetti</au><au>Venezia, Martina</au><au>Tomao, Silverio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current status of bevacizumab in advanced ovarian cancer</atitle><jtitle>OncoTargets and therapy</jtitle><addtitle>Onco Targets Ther</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>6</volume><spage>889</spage><epage>899</epage><pages>889-899</pages><issn>1178-6930</issn><eissn>1178-6930</eissn><abstract>Ovarian cancer is the most lethal gynecological cancer, mainly because of the delay in diagnosis. Recently, much effort has been put into investigating and introducing novel targeted agents into clinical practice, with the aim of improving prognosis and quality of life. Angiogenesis is a possible target. The aim of this review is to investigate the most common molecular pathways of angiogenesis, which have provided novel targets for tailored therapy in patients with ovarian cancer. These therapeutic strategies include monoclonal antibodies and tyrosine-kinase inhibitors. These drugs have as molecular targets vascular endothelial growth factor, vascular endothelial growth factor receptors, platelet-derived growth factor, fibroblast growth factor, and angiopoietin. Bevacizumab was investigated in several Phase III studies, with interesting results. Today, there is strong evidence for introducing bevacizumab in the treatment of patients with advanced and recurrent ovarian cancer. Nevertheless, further investigations and large clinical trials are needed to understand the safety and effectiveness of bevacizumab, the optimal duration and timing of treatment, and activity in association with other chemotherapeutic and targeted agents. It also is necessary to identify biologic factors predictive of efficacy to choose the most appropriate antiangiogenic agent in the integrated treatment of epithelial ovarian cancer.</abstract><cop>New Zealand</cop><pub>Dove Medical Press Limited</pub><pmid>23901283</pmid><doi>10.2147/OTT.S46301</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1178-6930
ispartof OncoTargets and therapy, 2013-01, Vol.6, p.889-899
issn 1178-6930
1178-6930
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3724566
source Open Access: PubMed Central; Taylor & Francis_OA刊; Publicly Available Content Database
subjects Angiogenesis
bevacizumab
chemotherapy
Drug therapy
epithelial ovarian cancer
Immunotherapy
Investigations
Medical case management
Medical research
Medicine, Experimental
Monoclonal antibodies
Ovarian cancer
Review
Targeted cancer therapy
Vascular endothelial growth factor
title Current status of bevacizumab in advanced ovarian cancer
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A16%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20status%20of%20bevacizumab%20in%20advanced%20ovarian%20cancer&rft.jtitle=OncoTargets%20and%20therapy&rft.au=Tomao,%20Federica&rft.date=2013-01-01&rft.volume=6&rft.spage=889&rft.epage=899&rft.pages=889-899&rft.issn=1178-6930&rft.eissn=1178-6930&rft_id=info:doi/10.2147/OTT.S46301&rft_dat=%3Cgale_pubme%3EA375815862%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c504t-3973496297d80f14a3adae5160d7fbc3ab9e23a2a9f2bf21fe427de219cec2bd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2222782115&rft_id=info:pmid/23901283&rft_galeid=A375815862&rfr_iscdi=true